Starting Hormone Therapy After 60: What the Evidence Actually Says

The window of opportunity — also called the timing hypothesis — is the idea that hormone therapy's effects on the cardiovascular system depend heavily on when you start it relative to menopause. Start within roughly 10 years of your final period, or before age 60, and the balance of benefits and risks looks favorable. Start much later and the same medication behaves differently in the body.

The mechanism proposed for this is about the state of your arteries. Estrogen appears to help maintain healthy, flexible blood vessel walls when they are still relatively healthy. But in arteries that have already developed atherosclerotic plaque — the fatty deposits that build up over years — introducing estrogen may destabilize existing plaque rather than prevent new plaque from forming. Same drug, different tissue environment, different result.

This explains one of the most confusing chapters in women's health. The Women's Health Initiative (WHI), published in 2002, reported increased cardiovascular events and stopped a generation of women from using hormone therapy. But the average participant was 63 years old and more than a decade past menopause — a population chosen to study disease prevention, not symptom relief in newly menopausal women. When the WHI data were later reanalyzed by age group, women who started in their fifties showed a very different and much more favorable pattern.

Subsequent trials designed specifically to test the timing question — KEEPS and ELITE, both published in the 2010s — supported the hypothesis. ELITE found that estrogen slowed the progression of artery thickening in women within six years of menopause but not in women more than 10 years out.

Our breakdown of [what the WHI data actually shows](/blog/hrt-and-breast-cancer-risk-what-the-whi-data-actually-shows) covers the breast cancer side of that same story.

The risks are real, specific, and worth understanding numerically rather than as a vague warning.

The clearest signal is stroke. Oral estrogen is associated with an increased risk of ischemic stroke, and because baseline stroke risk rises steeply with age, the same relative increase translates into a larger absolute number of events in a 65-year-old than in a 52-year-old. This is the core reason guidelines draw a line at 60 — not because something changes about the drug, but because the background risk it multiplies has grown.

The second is venous thromboembolism (VTE) — blood clots in the legs or lungs. Oral estrogen passes through the liver before entering general circulation, a process called first-pass metabolism, which increases production of clotting factors. Transdermal estrogen — patches, gels, sprays — bypasses the liver and observational studies consistently show little to no increase in clot risk with this route. This distinction matters enormously for anyone considering later initiation.

Coronary heart disease risk depends on the timing hypothesis discussed above. And breast cancer risk relates primarily to duration of combined estrogen-progestogen use rather than age at initiation, with risk increasing after roughly three to five years of combined therapy.

What is *not* on this list is worth noting. There is no evidence that starting later causes cognitive harm at any dose, and estrogen's bone-protective effects appear to work at any age — The Menopause Society notes there is no age after which estrogen stops benefiting bone.

For a fuller picture of cardiovascular changes in this stage of life, see our article on [menopause and stroke risk after 45](/blog/menopause-and-stroke-risk-what-changes-after-45).

Because symptoms do not politely stop at a round number. The assumption baked into a lot of medical advice is that vasomotor symptoms — hot flashes and night sweats — burn out within a few years. For many women they do not.

The SWAN study (Study of Women's Health Across the Nation), which has followed thousands of women through midlife since 1996, found that the median duration of frequent hot flashes was 7.4 years, and that women whose symptoms began early in perimenopause experienced them for more than 11 years on average. A meaningful minority of women are still having disruptive vasomotor symptoms into their sixties and seventies.

There are other paths to this decision. Some women were told in 2002 to stop hormone therapy immediately because of the WHI and are now revisiting a decision made on data that has since been reinterpreted. Some had a late natural menopause at 56 or 57, which puts them only a few years out at age 62 — well inside the 10-year window even though they are past the age-60 line. Some developed severe genitourinary syndrome of menopause (GSM) — vaginal dryness, pain with sex, recurrent urinary tract infections — which unlike hot flashes tends to worsen progressively with time rather than fade.

And some are facing significant osteoporosis risk and have not tolerated or responded to other treatments.

The point is that 'starting after 60' describes a wide range of very different clinical situations. A 61-year-old two years past menopause with debilitating night sweats and no cardiovascular risk factors is not in the same position as a 72-year-old with hypertension and 20 years since her last period.

In November 2025, the FDA announced it was initiating the removal of the boxed warning — the black-box label that has appeared on systemic hormone therapy products for over two decades — following an expert panel review.

That warning was added in the wake of the WHI and applied broadly, including to low-dose vaginal estrogen products that deliver almost no hormone into the bloodstream. Menopause specialists had argued for years that applying a cardiovascular and cancer warning derived from oral combined therapy in women averaging 63 years old to a vaginal cream used for dryness was scientifically indefensible and had deterred appropriate treatment.

What the change does and does not mean matters. It reflects a reassessment of how risk information is communicated — it does not mean the underlying risks were fabricated or have disappeared. Stroke and clot risk with oral estrogen in older initiators is still real. The FDA's own labeling guidance continues to reference initiation within 10 years of menopause or before age 60 for systemic therapy.

What it does change is the conversation. For years, the boxed warning functioned as a conversation-ender in primary care offices — a visible signal that the drug was dangerous, full stop. Removing it makes room for the individualized risk assessment that guidelines have actually recommended since 2017.

If you are weighing formulation choices, our comparison of [patch versus gel versus pill](/blog/hrt-patch-vs-gel-vs-pill-which-delivery-method-is-best) is directly relevant, since route of delivery is the single biggest modifiable risk factor for later initiators.

Quite a few, and several have solid trial evidence behind them.

Vaginal estrogen deserves its own category. Low-dose vaginal creams, rings, and tablets deliver estrogen locally with minimal systemic absorption, and they are effective for dryness, painful sex, and recurrent urinary tract infections. There is no upper age limit and the risk profile is entirely different from systemic therapy. If your primary problem is genitourinary rather than hot flashes, this is often the whole answer. See [vaginal estrogen for GSM](/blog/vaginal-estrogen-for-gsm-safety-types-and-what-to-expect) for the details.

Non-hormonal prescription options for hot flashes have expanded substantially. Fezolinetant (Veozah), approved in 2023, and elinzanetant (Lynkuet) are neurokinin receptor antagonists — they work on the brain's temperature control center directly rather than through hormones. In the SKYLIGHT trials, fezolinetant reduced hot flash frequency and severity meaningfully compared with placebo. SSRIs and SNRIs at low doses, and gabapentin for night-time symptoms, also have evidence. Our comparison of [Lynkuet versus Veozah](/blog/lynkuet-vs-veozah-nonhormonal-hot-flash-pills-compared) covers how they differ.

Cognitive behavioral therapy for menopause is recommended by NICE and has randomized trial support for reducing how bothersome hot flashes feel, even when it does not reduce their frequency.

For bone protection specifically, bisphosphonates, denosumab, and other osteoporosis medications are designed for exactly this population and do not carry the cardiovascular questions that estrogen does after 60.

Go in with specifics rather than a general question, because 'should I be on HRT?' invites a general answer.

Bring four pieces of information. First, your age at final period — not just your current age. The 10-year window is measured from menopause, not from birth, and a late menopause changes the calculation. Second, your actual symptoms and their impact: how many hot flashes per day, how many nights of disrupted sleep per week, what you have stopped doing because of them. Severity justifies risk in a way that vague discomfort does not. Third, your cardiovascular risk factors: blood pressure, cholesterol, smoking history, diabetes, family history of stroke or clots. Fourth, what you have already tried and how it went.

Then ask specific questions. Is transdermal appropriate for me given my clot risk? What is my calculated cardiovascular risk score? If we try this, what would make us stop? Do I need a progestogen, and which type? Is my bone density known, and does that change the calculation?

Be prepared for the possibility that your primary care clinician is not up to date. Menopause education in medical training has historically been minimal, and many clinicians formed their view during the post-WHI years. If you get a flat refusal without a risk discussion, a referral to a menopause specialist — or a certified menopause practitioner through The Menopause Society's directory — is a reasonable next step.

Our guide on [how to talk to your doctor about midlife treatment decisions](/blog/talking-to-your-doctor-about-glp1-and-menopause-what-to-ask) has a broader question list you can adapt.

Assuming you and your clinician decide the balance favors treatment, several choices reduce risk meaningfully.

Route first. Transdermal delivery — patch, gel, or spray — avoids first-pass liver metabolism and the associated increase in clotting factors. For anyone starting later, this is the single most important decision, and most menopause specialists consider oral estrogen difficult to justify as a first choice after 60.

Dose second. The guiding principle is the lowest dose that controls symptoms. Starting low and titrating up beats starting at a standard dose and hoping. Many later initiators find symptom control at doses below what a 51-year-old would need.

Progestogen if you have a uterus. Estrogen alone increases endometrial cancer risk in women with an intact uterus, so a progestogen is required for protection. Micronized progesterone is generally preferred over older synthetic progestins based on its more favorable breast and cardiovascular signal in observational data. Our explainer on [bioidentical versus synthetic hormones](/blog/bioidentical-vs-synthetic-hrt-what-the-difference-means) covers what those terms actually mean.

Monitoring and review. A three-month check to assess symptom response and tolerability, then annual review of whether continuing still makes sense. Blood pressure monitoring, mammography per screening guidelines, and prompt evaluation of any unexplained bleeding.

And know the stop signs: new chest pain, one-sided leg swelling or pain, sudden severe headache, vision changes, or symptoms of stroke require immediate medical attention, not a wait-and-see approach.

The overarching principle from The Menopause Society is that ongoing individualized hormone therapy appears to have no fixed age limit — but 'individualized' is doing real work in that sentence. It means the decision gets made with your numbers, not a rule of thumb.